- International Stem Cell Corporation (ISCO) and Dr. Andrey Semechkin, the Company's Co-Chairman and Chief Executive Officer, agreed on **September 15, 2025**, to **extend the maturity date** of a loan.  **[1355790_0001683168-25-007018_intlstemcell_8k.htm:1]** 
- The loan, which originated from a promissory note dated September 15, 2024, now has a maturity date of **September 15, 2026**.  **[1355790_0001683168-25-007018_intlstem_ex1001.htm:0]** **[1355790_0001683168-25-007018_intlstemcell_8k.htm:1]** 
- The outstanding principal balance of the loan is **$2,500,000**.  **[1355790_0001683168-25-007018_intlstem_ex1001.htm:0]** **[1355790_0001683168-25-007018_intlstemcell_8k.htm:1]** 
- This principal accrues interest at an annual rate of **5.5%**.  **[1355790_0001683168-25-007018_intlstem_ex1001.htm:0]** **[1355790_0001683168-25-007018_intlstemcell_8k.htm:1]** 
- Additionally, **$799,064.44** in accrued and unpaid interest from the original note is carried forward, which will not accrue further interest under the new agreement.  **[1355790_0001683168-25-007018_intlstem_ex1001.htm:0]**

International Stem Cell (ISCO)